有氧运动降低精神分裂症自杀风险的多中心随机试验方案
精神分裂症患者自杀风险高,现有药物和心理治疗降低风险效果有限。本研究采用多中心单盲随机临床试验设计,将患者随机分配至12周有氧运动或拉伸调理对照干预,主要结局为自杀风险(C-SSRS)和有氧适能(VO2max),并在基线、6周和12周评估。假设有氧运动可降低该人群自杀风险。
要点
- 精神分裂症患者终生自杀未遂率超40%,完成自杀估计5-10%。
- 有氧运动可能通过改善抑郁情绪和睡眠困难等自杀风险预测因子降低风险。
- 试验比较12周有氧运动与拉伸调理对照,主要结局为C-SSRS和VO2max。
核心结论
- 假设有氧运动可降低精神分裂症患者的自杀风险,并为该人群提供现有药物和心理治疗之外更有效的治疗选择。
研究设计与样本
- 多中心、单盲、随机临床试验,参与者随机分配至12周有氧运动或拉伸调理对照干预。
- 主要结局包括自杀风险(哥伦比亚自杀严重程度评定量表,C-SSRS)和有氧适能(VO2max),并在基线、6周和12周完成评估。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 精神分裂症患者终生自杀未遂率超过40%,完成自杀估计为5-10%。
- 干预时长12周,评估时间点为基线、6周和12周。
临床怎么用
- 若假设得到验证,有氧运动可作为精神分裂症患者降低自杀风险的辅助治疗手段。
局限性
- 原文为研究方案,尚未提供有氧运动降低自杀风险的实效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suicide risk among individuals with schizophrenia (SZ) is intractably high, with over 40% of individuals attempting to take their own lives during their lifetime and an estimated 5-10% completing suicide. At present, available pharmacological and psychotherapeutic treatments offer limited risk reduction benefits, and thus, there remains an urgent need to explore novel interventions that will ameliorate this risk. Aerobic exercise (AE) has been shown to improve a number of predictors of suicide risk (e.g., depressed mood, sleeping difficulties). As individuals with SZ display a highly sedentary lifestyle, AE may reduce suicide risk. METHODS: Employing a multi-site, single-blind, randomized clinical trial design, we will examine the impact of AE on risk for suicide and related variables in individuals with SZ. Participants will be randomized to one of two 12-week exercise interventions: AE or a stretching and toning (ST) control intervention. Primary outcome measures will include suicide risk (Columbia Suicide Severity Rating Scale, C-SSRS) and aerobic fitness (VO2max), along with additional measures of suicide risk, mood, emotion regulation, sleep, cognition, and physical activity, with assessments completed at baseline and after 6 and 12 weeks of interventions. DISCUSSION: It is hypothesized that AE will reduce suicide risk among individuals with SZ. This study may offer support for a more efficacious treatment method for this population in addition to the pre-existing pharmacological and psychotherapeutic treatment regimens. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03270098 . Registered on September 1, 2017.
引用
- Beck-Felts K, Goodman M, Ospina LH, et al. Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. Trials. 2020. PMID: 33087170. doi:10.1186/s13063-020-04788-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。